BR112012027813A2 - piperazinotriazinas como inibidores de pi3k para uso no tratamento de distúrbios antiproliferativos - Google Patents
piperazinotriazinas como inibidores de pi3k para uso no tratamento de distúrbios antiproliferativosInfo
- Publication number
- BR112012027813A2 BR112012027813A2 BR112012027813A BR112012027813A BR112012027813A2 BR 112012027813 A2 BR112012027813 A2 BR 112012027813A2 BR 112012027813 A BR112012027813 A BR 112012027813A BR 112012027813 A BR112012027813 A BR 112012027813A BR 112012027813 A2 BR112012027813 A2 BR 112012027813A2
- Authority
- BR
- Brazil
- Prior art keywords
- amino ethyl
- acryloyl
- piperazinotriazines
- treatment
- ethyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
Abstract
piperazinotriazinas como inibidores de pi3k para uso no tratamento de distúrbios antiproliferativos. a invenção refere-se a compostos de fórmula (i), em que r1 é metila, n-hexila, amino etila, metil amino etila, etil amino etila, dimetil amino etila, acriloil amino etila, metacriloil amino etila, metoxietila, etoxietila, d-c4-alquil sulfonila, acriloíla, ou metacriloíla; ou r1 é amino etila, acriloíla, ou acriloil amino atila transportando um ligante e uma etiqueta, e r2 e r3, independentemente um do outro, são hidrogênio ou crc4-alquila, ou r2 e r3 juntos formam uma ponte metileno ou etileno; e seus tautômeros, solvatos e sais farmaceuticamente aceitáveis. estes compostos são eficazes na prevenção ou tratamento de uma doença ou distúrbio modulado por pi3 cinases e/ou mtor, em particular tratamento de um distúrbio hiperproliferativo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1007227.0A GB201007227D0 (en) | 2010-04-30 | 2010-04-30 | Piperazinotriazines |
PCT/IB2011/051829 WO2011135520A1 (en) | 2010-04-30 | 2011-04-27 | Piperazinotriazines as pi3k inhibitors for use in the treatment antiproliferative disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112012027813A2 true BR112012027813A2 (pt) | 2018-05-15 |
Family
ID=42289874
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112012027813A BR112012027813A2 (pt) | 2010-04-30 | 2011-04-27 | piperazinotriazinas como inibidores de pi3k para uso no tratamento de distúrbios antiproliferativos |
Country Status (16)
Country | Link |
---|---|
US (1) | US20130040912A1 (pt) |
EP (1) | EP2563368A1 (pt) |
JP (1) | JP2013525419A (pt) |
KR (1) | KR20130118731A (pt) |
CN (1) | CN103002899A (pt) |
AU (1) | AU2011246952A1 (pt) |
BR (1) | BR112012027813A2 (pt) |
CA (1) | CA2797808A1 (pt) |
GB (1) | GB201007227D0 (pt) |
IL (1) | IL222692A0 (pt) |
MX (1) | MX2012012560A (pt) |
NZ (1) | NZ603859A (pt) |
RU (1) | RU2012151201A (pt) |
SG (1) | SG185067A1 (pt) |
WO (1) | WO2011135520A1 (pt) |
ZA (1) | ZA201206898B (pt) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2968345B1 (en) | 2013-03-13 | 2017-12-13 | The Regents of The University of Michigan | Dual mek/pi3k inhibitors and their application in the treatment of cancer diseases |
US9951040B2 (en) | 2014-11-20 | 2018-04-24 | Council Of Scientific And Industrial Research | 1,3,5 -triazine based PI3K inhibitors as anticancer agents and a process for the preparation thereof |
CN105130960B (zh) * | 2015-07-31 | 2018-07-06 | 沈阳药科大学 | 1,3,5-三嗪类衍生物及其应用 |
CN109563088B (zh) | 2016-07-06 | 2022-10-11 | 密歇根大学董事会 | MEK/PI3K和mTOR/MEK/PI3K的多功能抑制剂和治疗用途 |
CN109810100B (zh) * | 2017-11-21 | 2022-03-11 | 中国药科大学 | 含有苯并呋喃的parp-1和pi3k双靶点抑制剂 |
CN113200969B (zh) * | 2021-05-19 | 2022-11-25 | 中国药科大学 | 一种PI3Kα选择性抑制剂及其制备方法和应用 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DK1020462T3 (da) | 1997-07-24 | 2004-04-26 | Zenyaku Kogyo Kk | Heterocykliske forbindelser og antitumormiddel indeholdende disse som aktiv ingrediens |
DE60217322T2 (de) | 2001-04-27 | 2007-10-04 | Zenyaku Kogyo K.K. | Heterocyclische verbindung und antitumormittel, das diese als wirkstoff enthält |
JP2005531347A (ja) | 2002-07-01 | 2005-10-20 | アミジッチ,オグニエン | 試験人物の認知または感覚運動の能力もしくは才能を評価するために使用されるデータを生成するための方法 |
CA2507100C (en) * | 2002-11-21 | 2012-10-09 | Chiron Corporation | 2,4,6-trisubstituted pyrimidines as phosphotidylinositol (pi) 3-kinase inhibitors and their use in the treatment of cancer |
PT1864665E (pt) | 2005-03-11 | 2012-06-27 | Zenyaku Kogyo Kk | Agente imunossupressor compreendendo um composto heterocíclico como ingrediente activo |
WO2008032033A1 (en) | 2006-09-14 | 2008-03-20 | Astrazeneca Ab | 4-benzimidazolyl-2-morpholino-6-piperazinylpyrimidine derivatives as pi3k and mtor inhibitors for the treatment of proliferative disorders |
WO2009066084A1 (en) * | 2007-11-21 | 2009-05-28 | F. Hoffmann-La Roche Ag | 2 -morpholinopyrimidines and their use as pi3 kinase inhibitors |
EP2276750A2 (en) * | 2008-03-27 | 2011-01-26 | Auckland Uniservices Limited | Substituted pyrimidines and triazines and their use in cancer therapy |
US8513221B2 (en) * | 2008-07-07 | 2013-08-20 | Xcovery Holding, LLC | PI3K isoform selective inhibitors |
US8461158B2 (en) * | 2009-03-27 | 2013-06-11 | Pathway Therapeutics Inc. | Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy |
-
2010
- 2010-04-30 GB GBGB1007227.0A patent/GB201007227D0/en not_active Ceased
-
2011
- 2011-04-27 CA CA2797808A patent/CA2797808A1/en not_active Abandoned
- 2011-04-27 MX MX2012012560A patent/MX2012012560A/es not_active Application Discontinuation
- 2011-04-27 JP JP2013506793A patent/JP2013525419A/ja active Pending
- 2011-04-27 BR BR112012027813A patent/BR112012027813A2/pt not_active IP Right Cessation
- 2011-04-27 EP EP11723129A patent/EP2563368A1/en not_active Withdrawn
- 2011-04-27 WO PCT/IB2011/051829 patent/WO2011135520A1/en active Application Filing
- 2011-04-27 US US13/643,357 patent/US20130040912A1/en not_active Abandoned
- 2011-04-27 KR KR1020127031105A patent/KR20130118731A/ko not_active Application Discontinuation
- 2011-04-27 CN CN2011800215135A patent/CN103002899A/zh active Pending
- 2011-04-27 RU RU2012151201/04A patent/RU2012151201A/ru not_active Application Discontinuation
- 2011-04-27 AU AU2011246952A patent/AU2011246952A1/en not_active Abandoned
- 2011-04-27 NZ NZ603859A patent/NZ603859A/en not_active IP Right Cessation
- 2011-04-27 SG SG2012079679A patent/SG185067A1/en unknown
-
2012
- 2012-09-14 ZA ZA2012/06898A patent/ZA201206898B/en unknown
- 2012-10-25 IL IL222692A patent/IL222692A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
ZA201206898B (en) | 2013-07-31 |
GB201007227D0 (en) | 2010-06-16 |
IL222692A0 (en) | 2012-12-31 |
RU2012151201A (ru) | 2014-06-10 |
US20130040912A1 (en) | 2013-02-14 |
WO2011135520A8 (en) | 2012-09-27 |
CN103002899A (zh) | 2013-03-27 |
MX2012012560A (es) | 2012-12-17 |
AU2011246952A1 (en) | 2012-12-20 |
JP2013525419A (ja) | 2013-06-20 |
SG185067A1 (en) | 2012-12-28 |
KR20130118731A (ko) | 2013-10-30 |
CA2797808A1 (en) | 2011-11-03 |
EP2563368A1 (en) | 2013-03-06 |
WO2011135520A1 (en) | 2011-11-03 |
NZ603859A (en) | 2014-07-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR112074A2 (es) | Derivados de 2-carboxamida-cicloamino-urea como inhibidores de pi-3 | |
AR060631A1 (es) | Derivados de pirimidina y su uso como inhibidores de fosfatidilnositol 3-quinasa (pi3k) | |
BRPI0924183B8 (pt) | inibidores de cdk4/6 quinase, seus usos e sua forma cristalina iii, e formulação farmacêutica | |
BR112012027813A2 (pt) | piperazinotriazinas como inibidores de pi3k para uso no tratamento de distúrbios antiproliferativos | |
BR112012026767A2 (pt) | composto, sal farmaceuticamente aceitável de um composto, composição farmacêutica, método para tratar ou previnir distúrbios, e, uso de um composto ou sal | |
CR20120628A (es) | Morfolinopirimidinas y su uso en terapia | |
BR112014010576A2 (pt) | inibidores de neprilisina | |
BR112013021638A2 (pt) | "compostos inibidores de trk, seu uso e composições que os compreendem" | |
BR112012008147A2 (pt) | compostos heteroarílicos como inibidores da quinase | |
BR112014003237A2 (pt) | compostos de indazol, composições e métodos de uso | |
GT201400009A (es) | 4-imidazopiridazin-1-il-benzamidas y 4-imidazotriazin-1-il-benzamidas como inhibidores de btk | |
SV2010003767A (es) | Compuestos pirazolicos 436 | |
BR112012026950A2 (pt) | composto, e, uso de um composto | |
EA200901488A1 (ru) | Замещенные имидазолопиридазины, как ингибиторы липидкиназы | |
BR112013011580A2 (pt) | derivados de ácido bisfenil pentanoico substituído por amino como inibidores de nep | |
ECSP13012658A (es) | Composiciones y métodos para el tratamiento de la mielofibrosis | |
BR112013031402A2 (pt) | derivados de hidantoína como inibidores de kv3 | |
MX338707B (es) | Compuestos heterociclicos activadores de proteina cinasa activada por 5'-amp (ampk) y metodos para emplearlos. | |
BR112014005226A2 (pt) | derivados de benzonitrila como inibidores de cinase | |
EA201000947A1 (ru) | Производные тиазола, применимые в качестве ингибиторов киназы pi3 | |
BRPI1015367B8 (pt) | derivados imidazo[2,1-b][1,3,4]tiadiazol | |
BR112013029999A2 (pt) | derivados de tiazol | |
SG195106A1 (en) | Trpv4 antagonists | |
EA200900924A1 (ru) | Циклизованные производные как ингибиторы eg-5 | |
EA201300436A8 (ru) | Совместные кристаллы и соли ингибиторов ccr3 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2472 DE 22-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |